Ц.Сумъяа
Loading...
Товч нэр
Ц.Сумъяа
Бүтэн нэр
Цэрэндаваа Сумъяа
Латин нэр
Tserendavaa Sumiya
Албан тушаал
Ахлах багш
Боловсролын зэрэг
Доктор (Ph.D)
Харьяалал
ORCID
Scopus Author ID
12 results
Now showing 1 - 10 of 12
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Investigation of Serum oxLDL, anti-oxLDL Antibody, MMP-9 and hsCRP Levels in Patients with Angiographically Defined Ruptured of Coronary Plaques(OMICS Publishing Group, 2017); ; ; ;Shagdar, Zorigoo - Some of the metrics are blocked by yourconsent settings
Item type:Publication, GW26-e2958 To study involvement of serum matrix metalloproteinase-9 in pathogenesis of myocardial infarction(Elsevier BV, 2015-10-01); ; ;Zorigoo Shagdar - Some of the metrics are blocked by yourconsent settings
Item type:Publication, TCTAP A-017 To Study Other Biomarkers That Assess During Myocardial Infarction(Elsevier BV, 2016-04-01); ;Odkhuu Enkhtaiwan ;Zorigoo Shagdar ;Gandulam Chuluunkhuu - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Involvement of Serum Matrix Metalloproteinase-9 in the Pathogenesis of Acute Myocardial Infarction(Mongolian National University of Medical Sciences, 2016-11-25); ; ;Jung Rae Cho ;Namho LeeGandulam ChuluunkhuuObjectives: Prior studies indicate that matrix metalloproteinase-9 (MMP-9) plays a key role in pathogenesis of plaque rupture. The objective of this study was to evaluate the involvement of serum MMP-9 enzyme at pathogenesis of the plaque rupture in coronary atherosclerosis. Methods: The study enrolled 80 consecutive patients who underwent percutaneous coronary intervention in our institution. Inclusion in the case group (n = 40) required a ruptured coronary atherosclerotic plaque confirmed by conventional angiography, whereas inclusion in the control group (n = 40) required stable coronary atherosclerosis. Serum MMP-9 levels were determined by ELISA. Cardiac Infarction Injury Score (CIIS) by electrocardiogram and Gensini score (Coronary Angiographic Scoring System) were utilized for assessing the severity of coronary artery disease. Results: The average level of MMP-9 was significantly higher in the case group than in the control group (396±155 ng/mL vs. 223±87 ng/mL, p<0.001) with further demonstration that MMP-9 is an independent predictor of plaque rupture (β = 0.985, p><0.001). MMP-9 is well correlated with Gensini and CIIS score (r = 0.552, p ><0.01 and r = 0.340, p><0.01, respectively). Furthermore, serum MMP-9 enzyme significantly increased in accordance with the severity of the myocardium damage (p ><0.01) by CIIS score. Conclusion: MMP-9 plays a role at pathogenesis of plaque rupture in coronary atherosclerosis.><0.001) with further demonstration that MMP-9 is an independent predictor of plaque rupture (β = 0.985, p<0.001). MMP-9 is well correlated with Gensini and CIIS score (r = 0.552, p ><0.01 and r = 0.340, p><0.01, respectively). Furthermore, serum MMP-9 enzyme significantly increased in accordance with the severity of the myocardium damage (p ><0.01) by CIIS score. Conclusion: MMP-9 plays a role at pathogenesis of plaque rupture in coronary atherosclerosis.><0.001). MMP-9 is well correlated with Gensini and CIIS score (r = 0.552, p<0.01 and r=0.340, p<0.01, respectively). Furthermore, serum MMP-9 enzyme significantly increased in accordance with the severity of the myocardium damage (p<0.01) by CIIS score. Conclusion: MMP-9 plays a role at pathogenesis of plaque rupture in coronary atherosclerosis. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, TCTAP A-054 The Study Endothelial Nitric Oxide Synthase Enzyme of EPC Colonies in the Coronary Atherosclerosis(Elsevier BV, 2018-04); ;Enkhtaiwan, Odkhuu; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Elevated Levels of Anti-oxLDL Antibody in Relation with Acute Myocardial Infarction(Mongolian National University of Medical Sciences, 2021-07-01); ;Jung Rae ChoiObjectives: We aimed to determine the serum level of anti-oxLDL antibody at the involving of acute myocardial infarction. Methods: In the case-control study, patients with acute myocardial infarction (coronary stenosis > 85%) as determined by quantities coronary angiography in the case group (n = 26) and healthy people with carotid artery stenosis (< 0.7 mm) have been involved in the control group (n = 50). We determined Anti-oxLDL antibody and oxLDL titers by ELISA. Results: Anti-oxLDL antibody levels for the case group were greater than the control group (p < 0.01). Using binary logistic regression, the anti-oxLDL antibody was significantly associated with acute myocardial infarction (OR = 1.082, p < 0.01). Conclusions: Elevated serum anti-oxLDL antibodies may be a risk factor for developing acute myocardial infarction and concerning the correlation of anti-oxLDL antibodies and acute myocardial infarction - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Involvement of Endothelial Progenitor Cell Dysfunction in the Angiographically Defined Coronary Atherosclerotic Patients(Mongolian National University of Medical Sciences, 2020-09-25); ; ; Objectives: To evaluate the levels of endothelial progenitor cell-colony forming units in the angiographically defined coronary atherosclerotic patients. Methods: The 10 ml blood was drawn from the peripheral vein of 12-man patients that 4-stable angina, 4 acute myocardial infarction (AMI), and 4 healthy people. Peripheral blood mononuclear cells were isolated by Ficoll density-gradient centrifugation and EPC-CFUs was assayed after two plating and a 6-day culture on fibronectin-coated, 72 well plates, as described. eNOS enzyme titers were determined by ELISA according to the protocol in the cell culture. Results: The people were 52 ± 2.12 years. The number of EPC-CFUs increases with the accordance of patients with stable angina, AMI, healthy people with the statistical significance (H = 15.8, p < 0.001): stable angina (2.6 ± 0.47 colony/well), AMI (6.7 ± 0.81 colony/well), healthy people (10.5 ± 1.34 colony/well). Furthermore, the Kruskal–Wallis test of eNOS enzyme levels in patients with stable angina (5.2 ± 0.61 pg/ml), AMI (8.7 ± 1.49 pg/ml), and healthy people (13.7 ± 2.48 pg/ml). The significant difference (H = 5.7, p < 0.010) was observed among the three groups. The number of EPC-CFUs had a direct significant correlation (r = 0.621, p < 0.001) with the eNOS enzyme levels of this culture. Conclusions: The number of EPC-CFUs and eNOS enzyme levels decrease at patients with stable angina, indicate more than endothelial dysfunction. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study(2017-09) ;Choi, Jae Hyuk ;Cho, Jung Rae ;Park, Sang Min ;Shaha, Kunal BikramPierres, FloydPURPOSE: The purpose of this study was to assess the potential benefit of a 5-hydroxytryptamine receptor antagonist, sarpogrelate-based triple antiplatelet therapy (TAPT) in comparison with dual antiplatelet therapy (DAPT) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). MATERIALS AND METHODS: 119 patients of STEMI were retrospectively assessed. All patients received aspirin and clopidogrel per standard of care. Among them, 53 patients received an additional loading dose of sarpogrelate and a maintenance dose for 6 months post-PCI (TAPT group), while others did not (DAPT group). RESULTS: The rates of complete ST-segment resolution at 30 minutes post-PCI and post-procedural thrombolysis in myocardial infarction flow were not significantly different between the two groups (52.8% vs. 48.5%, p=0.200; 92.5% vs. 89.4%, p=0.080). In addition, no significant differences were observed between the two groups with regard to 30-day and 12-month clinical outcomes (cardiac death, myocardial infarction, stent thrombosis, target vessel revascularization, and severe bleeding). Meanwhile, improvement in left ventricular (LV) systolic function was observed in the TAPT group [ΔLV ejection fraction (LVEF)=17.1±9.4%, p<0.001; Δglobal longitudinal strain (GLS)=-9.4±4.2% , p<0.001] at 6 months, whereas it was not in the DAPT group (ΔLVEF= 8.8±6.5%, p=0.090; ΔGLS=-4.6±3.4%, p=0.106). In multivariate analyses, TAPT was an independent predictor for LV functional recovery (odds ratio, 2.61; 95% confidence interval, 1.16-5.87; p=0.003). CONCLUSION: Sarpogrelate-based TAPT improved LV systolic function at 6 months in STEMI patients undergoing primary PCI.Scopus© Citations 9
